| アブストラクト | BACKGROUND: Hyperkalemia (HK) is a barrier to optimization of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy in heart failure (HF) and chronic kidney disease (CKD). We investigated cardiorenal risk associated with changes in RAASi regimen after an episode of HK in patients with HF and/or CKD. METHODS: This observational study utilized data from hospital records, claims, and health registers from the US (Optum's de-identified Market Clarity Data) and Japan (Medical Data Vision). Included patients had an index episode of HK between July 2019 and September 2021 (US), or May 2020 and September 2021 (Japan), with prior diagnosis of HF or CKD (stage 3 or 4), and RAASi use. Risk of a cardiorenal composite outcome (HF emergency visit, HF hospitalization, or progression to end-stage kidney disease) was determined in patients who discontinued RAASi, down-titrated their dose by > 25%, or maintained or up-titrated their dose following the HK episode. RESULTS: A total of 15,488 and 6020 patients were included from the US and Japan, respectively. Prior to the episode of HK, 59% (US) and 27% (Japan) of patients had achieved > 50% target RAASi dose. Following the episode of HK, 33% (US) and 32% (Japan) of patients did not fill a new RAASi prescription. Risk of the cardiorenal outcome at 6 months was higher in patients who discontinued or down-titrated versus maintained or up-titrated RAASi treatment both in the US (17.5, 18.3, and 10.6%; p < 0.001) and in Japan (19.7, 20.0, and 15.1%; p < 0.001). CONCLUSION: HK-related RAASi discontinuation or down-titration was associated with higher risk of cardiorenal events versus maintained or up-titrated RAASi. |
|---|
| 投稿者 | Kanda, Eiichiro; Rastogi, Anjay; Murohara, Toyoaki; Lesen, Eva; Agiro, Abiy; Arnold, Matthew; Chen, Gengshi; Yajima, Toshitaka; Jarbrink, Krister; Pollack, Charles V Jr |
|---|
| 組織名 | Department of Medical Science, Kawasaki Medical School, 577 Matsushima,;Kurashiki, Okayama, 701-0192, Japan. kms.cds.kanda@gmail.com.;Department of Medicine, David Geffen School of Medicine at the University of;California Los Angeles, Los Angeles, CA, USA.;Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya,;Japan.;Medical & Payer Evidence, Cardiovascular, Renal and Metabolism,;BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;US Evidence, Medical Affairs, BioPharmaceuticals R&D, AstraZeneca, DE,;Wilmington, USA.;Real World Science and Digital, AstraZeneca, Cambridge, UK.;Health Economics & Payer Evidence, AstraZeneca, Cambridge, UK.;CVRM TA, Medical Affairs, AstraZeneca, Tokyo, Japan.;Department of Emergency Medicine, University of Mississippi School of Medicine,;Jackson, MS, USA. |
|---|
